Best practices for intrathecal drug delivery for pain

Joshua Prager, Timothy Deer, Robert Levy, Brian Bruel, Eric Buchser, David Caraway, Michael Cousins, Marilyn Jacobs, Gail McGlothlen, Richard Rauck, Peter Staats, Lisa Stearns

Research output: Contribution to journalArticle

Abstract

Objective The objective of this study was to identify best practices and provide guidance to clinicians to ensure safety and optimize intrathecal drug delivery for chronic intractable pain. Methods Twelve experienced pain medicine practitioners - eight anesthesiologists, one neurosurgeon, one physiatrist, one clinical psychologist, and one advanced practice registered nurse - from the United States, Australia, and Europe gathered to identify and publish consensus on best practices in three areas related to safe intrathecal therapy for pain: safety and monitoring, patient and device management, and patient selection and trialing. Conclusions Intrathecal drug delivery is a valuable alternative drug delivery system for many patients with severe chronic or end-of-life pain. While device-related complications (mostly with catheters) and surgical-site infections can occur, the main therapy-related safety issues associated with intrathecal drug delivery arise primarily with inadequate patient monitoring (e.g., respiratory depression), inflammatory mass (e.g., high doses and concentrations of opioids), wound healing, dosing errors (e.g., medication concentration and pump programming), pump fills or refills (e.g., pocket fills), and interaction with concomitant systemic medications (e.g., opioids and benzodiazepines). Many of the reported adverse events and complications of intrathecal drug delivery can be prevented by adequate clinician training, implementation of best practices, and experience. In adopting the therapy, patients must be apprised of its risks and benefits. Physicians and patients must partner to achieve both safety and effectiveness.

Original languageEnglish (US)
Pages (from-to)354-372
Number of pages19
JournalNeuromodulation
Volume17
Issue number4
DOIs
StatePublished - 2014
Externally publishedYes

Fingerprint

Practice Guidelines
Pain
Physiologic Monitoring
Safety
Pharmaceutical Preparations
Opioid Analgesics
Surgical Wound Infection
Intractable Pain
Medication Errors
Equipment and Supplies
Drug Delivery Systems
Patient Safety
Benzodiazepines
Chronic Pain
Respiratory Insufficiency
Wound Healing
Patient Selection
Consensus
Therapeutics
Catheters

Keywords

  • Best practices
  • chronic pain
  • intrathecal catheter
  • intrathecal drug delivery
  • intrathecal pump
  • morphine
  • opioid
  • ziconotide

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neurology
  • Clinical Neurology

Cite this

Prager, J., Deer, T., Levy, R., Bruel, B., Buchser, E., Caraway, D., ... Stearns, L. (2014). Best practices for intrathecal drug delivery for pain. Neuromodulation, 17(4), 354-372. https://doi.org/10.1111/ner.12146

Best practices for intrathecal drug delivery for pain. / Prager, Joshua; Deer, Timothy; Levy, Robert; Bruel, Brian; Buchser, Eric; Caraway, David; Cousins, Michael; Jacobs, Marilyn; McGlothlen, Gail; Rauck, Richard; Staats, Peter; Stearns, Lisa.

In: Neuromodulation, Vol. 17, No. 4, 2014, p. 354-372.

Research output: Contribution to journalArticle

Prager, J, Deer, T, Levy, R, Bruel, B, Buchser, E, Caraway, D, Cousins, M, Jacobs, M, McGlothlen, G, Rauck, R, Staats, P & Stearns, L 2014, 'Best practices for intrathecal drug delivery for pain', Neuromodulation, vol. 17, no. 4, pp. 354-372. https://doi.org/10.1111/ner.12146
Prager J, Deer T, Levy R, Bruel B, Buchser E, Caraway D et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17(4):354-372. https://doi.org/10.1111/ner.12146
Prager, Joshua ; Deer, Timothy ; Levy, Robert ; Bruel, Brian ; Buchser, Eric ; Caraway, David ; Cousins, Michael ; Jacobs, Marilyn ; McGlothlen, Gail ; Rauck, Richard ; Staats, Peter ; Stearns, Lisa. / Best practices for intrathecal drug delivery for pain. In: Neuromodulation. 2014 ; Vol. 17, No. 4. pp. 354-372.
@article{cfe0cbb575bc43ebb0741162fe3eff16,
title = "Best practices for intrathecal drug delivery for pain",
abstract = "Objective The objective of this study was to identify best practices and provide guidance to clinicians to ensure safety and optimize intrathecal drug delivery for chronic intractable pain. Methods Twelve experienced pain medicine practitioners - eight anesthesiologists, one neurosurgeon, one physiatrist, one clinical psychologist, and one advanced practice registered nurse - from the United States, Australia, and Europe gathered to identify and publish consensus on best practices in three areas related to safe intrathecal therapy for pain: safety and monitoring, patient and device management, and patient selection and trialing. Conclusions Intrathecal drug delivery is a valuable alternative drug delivery system for many patients with severe chronic or end-of-life pain. While device-related complications (mostly with catheters) and surgical-site infections can occur, the main therapy-related safety issues associated with intrathecal drug delivery arise primarily with inadequate patient monitoring (e.g., respiratory depression), inflammatory mass (e.g., high doses and concentrations of opioids), wound healing, dosing errors (e.g., medication concentration and pump programming), pump fills or refills (e.g., pocket fills), and interaction with concomitant systemic medications (e.g., opioids and benzodiazepines). Many of the reported adverse events and complications of intrathecal drug delivery can be prevented by adequate clinician training, implementation of best practices, and experience. In adopting the therapy, patients must be apprised of its risks and benefits. Physicians and patients must partner to achieve both safety and effectiveness.",
keywords = "Best practices, chronic pain, intrathecal catheter, intrathecal drug delivery, intrathecal pump, morphine, opioid, ziconotide",
author = "Joshua Prager and Timothy Deer and Robert Levy and Brian Bruel and Eric Buchser and David Caraway and Michael Cousins and Marilyn Jacobs and Gail McGlothlen and Richard Rauck and Peter Staats and Lisa Stearns",
year = "2014",
doi = "10.1111/ner.12146",
language = "English (US)",
volume = "17",
pages = "354--372",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Best practices for intrathecal drug delivery for pain

AU - Prager, Joshua

AU - Deer, Timothy

AU - Levy, Robert

AU - Bruel, Brian

AU - Buchser, Eric

AU - Caraway, David

AU - Cousins, Michael

AU - Jacobs, Marilyn

AU - McGlothlen, Gail

AU - Rauck, Richard

AU - Staats, Peter

AU - Stearns, Lisa

PY - 2014

Y1 - 2014

N2 - Objective The objective of this study was to identify best practices and provide guidance to clinicians to ensure safety and optimize intrathecal drug delivery for chronic intractable pain. Methods Twelve experienced pain medicine practitioners - eight anesthesiologists, one neurosurgeon, one physiatrist, one clinical psychologist, and one advanced practice registered nurse - from the United States, Australia, and Europe gathered to identify and publish consensus on best practices in three areas related to safe intrathecal therapy for pain: safety and monitoring, patient and device management, and patient selection and trialing. Conclusions Intrathecal drug delivery is a valuable alternative drug delivery system for many patients with severe chronic or end-of-life pain. While device-related complications (mostly with catheters) and surgical-site infections can occur, the main therapy-related safety issues associated with intrathecal drug delivery arise primarily with inadequate patient monitoring (e.g., respiratory depression), inflammatory mass (e.g., high doses and concentrations of opioids), wound healing, dosing errors (e.g., medication concentration and pump programming), pump fills or refills (e.g., pocket fills), and interaction with concomitant systemic medications (e.g., opioids and benzodiazepines). Many of the reported adverse events and complications of intrathecal drug delivery can be prevented by adequate clinician training, implementation of best practices, and experience. In adopting the therapy, patients must be apprised of its risks and benefits. Physicians and patients must partner to achieve both safety and effectiveness.

AB - Objective The objective of this study was to identify best practices and provide guidance to clinicians to ensure safety and optimize intrathecal drug delivery for chronic intractable pain. Methods Twelve experienced pain medicine practitioners - eight anesthesiologists, one neurosurgeon, one physiatrist, one clinical psychologist, and one advanced practice registered nurse - from the United States, Australia, and Europe gathered to identify and publish consensus on best practices in three areas related to safe intrathecal therapy for pain: safety and monitoring, patient and device management, and patient selection and trialing. Conclusions Intrathecal drug delivery is a valuable alternative drug delivery system for many patients with severe chronic or end-of-life pain. While device-related complications (mostly with catheters) and surgical-site infections can occur, the main therapy-related safety issues associated with intrathecal drug delivery arise primarily with inadequate patient monitoring (e.g., respiratory depression), inflammatory mass (e.g., high doses and concentrations of opioids), wound healing, dosing errors (e.g., medication concentration and pump programming), pump fills or refills (e.g., pocket fills), and interaction with concomitant systemic medications (e.g., opioids and benzodiazepines). Many of the reported adverse events and complications of intrathecal drug delivery can be prevented by adequate clinician training, implementation of best practices, and experience. In adopting the therapy, patients must be apprised of its risks and benefits. Physicians and patients must partner to achieve both safety and effectiveness.

KW - Best practices

KW - chronic pain

KW - intrathecal catheter

KW - intrathecal drug delivery

KW - intrathecal pump

KW - morphine

KW - opioid

KW - ziconotide

UR - http://www.scopus.com/inward/record.url?scp=84903543641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903543641&partnerID=8YFLogxK

U2 - 10.1111/ner.12146

DO - 10.1111/ner.12146

M3 - Article

C2 - 24446870

AN - SCOPUS:84903543641

VL - 17

SP - 354

EP - 372

JO - Neuromodulation

JF - Neuromodulation

SN - 1094-7159

IS - 4

ER -